TOP - November 2022 Vol 15, No 6
GemCis with or without CPI-613 as First-Line Treatment for Patients with Advanced Biliary Tract Cancers
Factors Associated with Greater Risk for Abemaciclib Discontinuation in Patients with Early-Stage Breast Cancer
Several baseline factors were associated with an increased risk for treatment discontinuation in the phase 3 monarchE clinical trial, which assessed adjuvant abemaciclib (Verzenio) in patients with hormone receptor–positive, HER2-negative early breast cancer, according to findings from a multivariate analysis presented during the 2022 American Society of Clinical Oncology Annual Meeting.
Determination Trial Confirms Importance of Individualizing Therapy for Newly Diagnosed Multiple Myeloma
In the phase 3 DETERMINATION trial—in which patients with newly diagnosed multiple myeloma were randomly assigned to a standard triplet regimen with and without autologous stem-cell transplantation (ASCT), with all receiving lenalidomide (Revlimid) maintenance therapy until disease progression—patients with ASCT had significantly longer progression-free survival (PFS) versus those who did not, but no difference in overall survival (OS) was observed between the 2 treatment arms.
The November issue of The Oncology Pharmacist (TOP) contains the latest news and updates relevant to today’s pharmacy professionals working in the field of oncology. We begin our coverage with highlights from key sessions held during the European Society for Medical Oncology Congress 2022, where experts presented data from clinical trials assessing new diagnostic and therapeutic strategies aimed at improving outcomes for patients with cancer.
Endocrine therapy after breast-conserving surgery may be the only treatment needed in patients aged ≥55 years with low-grade luminal type A breast cancer, sparing them radiation therapy, including its side effects, financial burden, and inconvenience, according to findings from the single-arm LUMINA clinical trial reported at the 2022 American Society of Clinical Oncology Annual Meeting.
Adding Pembrolizumab to Chemotherapy Extends Survival in Women with Cervical Cancer Across Several Key Subgroups
The addition of pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) resulted in significantly and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) in women with cervical cancer.
Page 1 of 2
Results 1 - 10 of 11
Results 1 - 10 of 11